Prolaris predictor of metastatic disease, with no difference in predictive performance between races or treatment groups.
“Contrary to expectation, this study provides no evidence that African American men have more aggressive disease than non-African American men after accounting for all available molecular and clinicopatholgic prognostic information.”
Bardot S, Canter D, Reid J, et al. Comparing the prognostic utility of the CCP score for predicting metastatic disease in African American and Non-African American men with prostate cancer. Presented at American Urological Association annual meeting, May 2017.
Learn More Download Poster View Presentation